Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Covid-19 - Nigeria Approves Booster Doses for Enhanced Protection

12/04/2021 | 09:06am EST

The Nigerian government has said it will begin the administration of the COVID-19 booster dose for eligible Nigerians from December 10, across all states of the federation.

A statement released by the National Primary Health Care Development Agency (NPHCDA) on Friday evening noted that the booster doses will only be administered on Nigerians who have completed the two doses of Astrazeneca, Moderna or Pfizer Bio-N-Tech or one dose of Johnson and Johnson vaccines.

The executive director, NPHCDA, Faisal Shuaib, noted in the statement that the booster dose is strictly for persons 18 years and above.

According to Mr Shuaib, a COVID-19 booster dose gives greater protection against the virus. He urged all Nigerians to take advantage of the opportunity offered by the government.

He added that Nigerians are eligible for the booster dose if they have received the second dose of AstraZeneca, Moderna or Pfizer Bio-N-Tech within a time interval of six months or more, while two months for Johnson and Johnson vaccine.

"Consequent upon the above, eligible Nigerians are advised to visit the nearest health facility or mass vaccination site for their booster doses as from the 10th of December, 2021 across all states of the federation," the official said.

Vaccination goal

Before the discovery of Omicron variant, which has heightened concerns on how to curb the spread of COVID-19, Nigeria had set a goal of vaccinating 40 per cent of its over 200 million population before the end of 2021, and 70 per cent by the end of 2022.

But as of November 8, 2021, the NPHCDA said it has vaccinated 5,770,899 eligible persons with the first dose of the COVID-19 vaccination while 3,146,885 have taken the second dose.

The director, planning research and statistics, NPHCDA, Abdullahi Garba, disclosed that these figures were achieved in the 36 states and the FCT.

He noted that there were over eight million doses of vaccines in the country at the moment, but the country was still expecting more doses.

According to the latest Reuters COVID-19 tracker, Nigeria has administered about 10.1 million doses of COVID-19 vaccines so far.

Nigeria COVID-19 Status

Since the pandemic began in 2020, Nigeria has recorded 214,317 infections and 2,978 coronavirus fatalities across the 36 states of the federation and the Federal Capital Territory (FCT).

With over 3.5 million samples tested, Nigeria has successfully treated and discharged 207,370 patients while the latest data from NCDC also showed that about 3,969 people are still down with the disease.

Copyright Premium Times. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.48% 8728 Delayed Quote.1.06%
JOHNSON & JOHNSON -0.44% 167.1 Delayed Quote.-1.89%
MODERNA, INC. -8.85% 186.61 Delayed Quote.-19.39%
All news about ASTRAZENECA PLC
05:51pIMFINZI« (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line..
BU
05:44pAstraZeneca Says Imfinzi Plus Chemotherapy Shows 20% Reduction in Risk of Death in Adva..
MT
05:21pIMFINZI« (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanc..
BU
05:12pASTRAZENECA : Imfinzi plus tremelimumab demonstrated unprecedented survival in 1st-line un..
PU
05:12pASTRAZENECA : Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced ..
PU
06:02aFDA Grants Priority Review to AstraZeneca's Enhertu for Treatment of HER2-Positive Meta..
MT
01/17CORRECTING and REPLACING ENHERTU« granted Priority Review in the US for patients with H..
BU
01/17Enhertu granted Priority Review in the US for patients with HER2-positive metastatic br..
AQ
01/17Cline Scientific extends collaboration agreement with AstraZeneca
AQ
01/17AstraZeneca's Enhertu Granted Priority Review by US Regulator
DJ
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 081 M - -
Net income 2021 2 718 M - -
Net Debt 2021 24 811 M - -
P/E ratio 2021 39,8x
Yield 2021 3,22%
Capitalization 135 B 184 B -
EV / Sales 2021 4,44x
EV / Sales 2022 3,62x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 87,27 $
Average target price 138,66 $
Spread / Average Target 58,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC1.06%185 566
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.10%325 363
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
NOVO NORDISK A/S-15.01%223 075